Mologen extends clinical study to include another dosing group

28-Jul-2009 - Germany

Following positive interim results in the current clinical study with Mologen AG's cancer drug MGN1703, the authorities responsible have approved an extension of the study to include an additional dosing group. This means that the company can now start prompt investigation of the maximum dosage of 60 mg per treatment with two courses of treatment per week. Initial results achieved with this additional dosing group will probably be available towards the end of the third quarter of 2009.

The cancer drug MGN1703 is a DNA-based immune modulator that is being developed for immune therapy with patients who have solid tumours.

Since the patients' response to the innovative new cancer drug in the phase I clinical study has exceeded all expectations, the Management Board of the company took a decision in May to extend the study to include another dosing group. The additional amounts of the cancer drug MGN1703 needed for this purpose have in the meantime been produced, filled and packaged.

The preliminary evaluation of its effectiveness and its positive safety profile indicate that MGN1703 has high potential to at least stabilise the basic illness in the form of an advanced solid tumour with the patient population selected: more than 40 per cent of the patients were in a stable condition after completion of the 6-week course of treatment.

Mologen AG is currently making intensive preparations for additional clinical studies, in which the effectiveness of MGN1703 will be investigated. Phase 2 of the clinical study on patients with colorectal cancer is scheduled to start this year.

https://www.bionity.com/en/news/103843/mologen-extends-clinical-study-to-include-another-dosing-group.html